The major H-bond interactions are observed with Thr347. In pursuit to identify novel ERα inhibitory ligands, virtual screening was carried out by docking pyrazole, bipyrazole, thiazole, thiadiazole etc scaffold analogs from literature.34 bipyrazoles from literature revealed Compound 2,.9 kcal/mol binding affinity with the receptor, where a favourable H-bond was formed with Thr347.On the other hand, screening 2035 FDA approved drugs from Drug Bank database resulted in 11 drugs which showed better binding affinities than ERα bound tamoxifen. Consensus scoring using 5 scoring schemes such as Mol Dock score, mcule, SwissDock, Pose&Rank and DSX respectively resulted in better rank-sumsfor Lomitapide, Itraconazole, Cobicistat, Azilsartanmedoxomil, and Zafirlukast.
Background:
Majority of breast cancers diagnosed today are estrogen receptor (ER)-positive, where, estrogen binds to estrogen receptors on the surface of the cell [1] . According to the American Cancer Society, about 2 out of every 3 cases of breast cancer is hormone receptorpositive. However, in certain cases, progesterone receptor-positive (PR-positive) is also responsible for breast cancer [2] . Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ERα-positive breast cancer is more resistant to chemotherapy than ERα-negative cancer [3] . Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer is known. ERα plays an important role in determining the sensitivity of breast cancer cells to chemotherapeutic agents in vitro [4] . Down regulation of Aurora-A overrides estrogen-mediated growth and chemo resistance in breast cancer cells. Patients with ER-α-positive tumors have a slightly better survival rate than patients with ER-α-negative. However, both the ER and PR respond to the drug tamoxifen, designed to interfere the function of ER-α [5] . Tamoxifen decreases the incidence of invasive and non-invasive breast cancer. In spite of the tamoxifen administered side effects, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease [6] . ER-α is thought to function as a ligand-activated transcription factor. Extracellular signals can also stimulate ER-α-mediated transcription in the absence of estrogen. Stimulated ER-α can influence gene expression by associating with other transcription factors without binding directly to DNA
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©Biomedical Informatics (2019) Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway [7] [8] . Specific binding sites for estrogen at the outer surfaces of isolated endometrial cells are known. Estrogens stimulate growth of many breast cancer cells. Reducing estrogen levels or blocking often leads to a clinical response in patients with receptor-positive disease. In premenopausal women, estrogen production is high and in postmenopausal women relatively small amounts of estrogens are produced. These low levels of estrogens can be inhibited either by blocking the estrogen receptor, or by inhibiting the peripheral conversion of androgens to estrogens [9] . The most widely accepted pharmacologic endocrine therapies for breast cancer are treatment with anti estrogens [10] . Tamoxifen has been shown to be effective in both premenopausal women as well as in postmenopausal women [11] . Tamoxifen is the most widely used and extensively studied anti estrogen and its role in the management of patients with breast cancer is well established [12] . However, extensive evaluation of tamoxifen treatment revealed significant side effects such as endometrial cancer, blood clots and the development of acquired resistance. Hence, there is a pressing need for the improvement and/or development of new antiestrogens for the prevention and treatment of breast cancer.
Materials & Methods:
Receptor structure for molecular docking: 
Results and Discussion:
The crystal structure of human estrogen receptor alpha ligand binding domain in complex with 4-hydroxytamoxifen (PDB ID: 3ERT) was used for the docking. A thorough analysis of the X-ray crystal structure of estrogen receptor revealed that the active site regions has flexible amino acid side chains and hence could accommodate different chemical scaffolds. The amino acid residues lining active site are: Phe404, Glu419, Leu428, Met343, Gly420, Met421, Leu525, Gly521, Thr347, Leu387, Asp351, Ala350, Glu353, Trp383, Arg394, Leu346, respectively. The protein was prepared using Molegro software. All bond orders and hybridization were assigned, hydrogen and other missing atoms were added to the residues and charges were assigned. The co-crystallized water molecules were excluded from docking. Cavities in the protein were evaluated by Cavity detection algorithm using Expanded Van der Waals molecular surface with default parameters such as minimum and maximum cavity volume set at 10 and 10000 Å, with 1.20 Å probe radius and grid resolution being 0. Figure 1 and the h-bond interactions are given in Table 3 .
An electrostatic interaction was observed when the ligand interacted with oxygen atoms of Asp351. On the other hand, all other interacting amino acids displayed H-bond forces. Further, careful observations on the interacting amino acid residues revealed that pyrazolo[1,5-a]pyrimidine analogs under 11 series displayed major interactions with Thr347 whereas the 3-aryl-4-anilino-2H-chromen-2-ones reported under 14 series interacted majorly with His524 amino acid. The ERα bound tamoxifen displayed favourable interactions with Asp351 and Arg394, respectively. Similar interactions are observed with majority of the 14 series chromene derivatives.
Set-2: ERα Non-tested ligands from literature
A thorough literature search was made on structural features of ligands that would fit into the active site region of ERα, which resulted in pyrazole, bipyrazole, thiazole, thiadiazoleetc scaffold analogs. Bipyrazoles are known to possess inhibitory properties against several classes of enzymes. Moreover, preliminary docking analysis revealed better inhibition of ERα with bipyrazoles. Other classes of compounds displayed reduced inhibition. Hence, bipyrazoles are considered for further analysis.
Computational molecular docking and structural specificity of bipyrazoles as inhibitors of ERα
Docking of all 34 bipyrazoles from literature was carried out to evaluate the best conformer based on the lowest docked energy (kcal/mol) ( Table 4) , in other words, it should possess highest affinity towards the binding site [42] .
From the bipyrazole Vs ERα docking analysis output, it is evidenced that the bipyrazoles are able to bind and fit into the geometrical space provided by the active site region of ERα. The binding orientations of all bipyrazoles were similar to the cocrystallized ligand, tamoxifen (Figure 2) . The best compound 2 Table- 
(ethyl 5-amino-1-(5-amino-3-anilino-4-ethoxycarbonyl-pyrazol-1-yl)-3-anilino-pyrazole-4-carboxylate) from
4 5-(4-chlorophenyl)-4-(4-cyanopyrazol-1-yl)-N-(4-phenylphenyl)-3,4- dihydropyrazole-2-carboxamide Clc1ccc(cc1)C2=NN(CC2n3cc(cn3)C#N)C(=O) Nc4ccc(cc4)c5ccccc5 -139.765 5 1-(1,5-diphenylpyrazol-4-yl)-3,5-dimethyl-pyrazole Cc1cc(C)n(n1)c2cnn(c3ccccc3)c2c4ccccc4 -131.507 6 methyl 4-(3,5-dimethylpyrazol-1-yl)-5-phenyl-pyrazole-1-carboxylate COC(=O)n1ncc(c1c2ccccc2)n3nc(C)cc3C -120.717 7 1-tert-butyl-4-(3,5-dimethylpyrazol-1-yl)-5-phenyl-pyrazole Cc1cc(C)n(n1)c2cnn(c2c3ccccc3)C(C)(C)C -117.359 8 bis(2-adamantyl)-[2-[1-(4-methoxyphenyl)-3,5-diphenyl-pyrazol-4-yl]pyrazol-3- yl]phosphane COc1ccc(cc1)n2nc(c3ccccc3)c(c2c4ccccc4)n5nccc5P(C6C7CC8CC(CC6C8)C7) C9C%10CC%11CC(CC9C%11) C%10 -146.054 9 dicyclohexyl-[2-[1-(4-methoxyphenyl)-3,5-diphenyl-pyrazol-4-yl]pyrazol-3- yl]phosphane COc1ccc(cc1)n2nc(c3ccccc3)c(c2c4ccccc4)n5nccc5P (C6CCCCC6)C7CCCCC7 -148.556 10 ditert-butyl-[2-[1-(4-methoxyphenyl)-3,5-diphenyl-pyrazol-4-yl]pyrazol-3- yl]phosphane COc1ccc(cc1)n2nc(c3ccccc3)c(c2c4ccccc4)n5nccc5P(C(C)(C)C)C(C)(C)C -147.159 11 4-chloro-1-(3,5-dinitro-1H-pyrazol-4-yl)-5-nitro-pyrazole [O-][N+](=O)c1n[nH]c(c1n2ncc(Cl)c2[N+](=O)[O-])[N+](=O)[O-] -110.157 12 1-(3,5-dinitro-1H-pyrazol-4-yl)-4,5-dinitro-pyrazole [O-][N+](=O)c1cnn(c1[N+](=O)[O-])c2c(n[nH]c2[N+](=O)[O-])[N+](=O)[O-] -117.658 13 1-methyl-3,4-dinitro-5-(3-nitropyrazol-1-yl)pyrazole Cn1nc(c(c1n2ccc(n2)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-] -109.876 14 1-methyl-3,4-dinitro-5-(4-nitropyrazol-1-yl)pyrazole Cn1nc(c(c1n2cc(cn2)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-] -23 1-(4-nitrophenyl)-3-[1-(4-nitrophenyl)-5-propyl-pyrazol-3-yl]-5-propyl-pyrazole CCCc1cc(nn1c2ccc(cc2)[N+](=O)[O-])c3cc(CCC)n (n3)c4ccc(cc4)[N+](=O)[O-] -154.386 24 5-isopropyl-3-[5-isopropyl-1-(4-nitrophenyl)pyrazol-3-yl]-1-(4- nitrophenyl)pyrazole CC(C)c1cc(nn1c2ccc(cc2)[N+](=O)[O-])c3cc(C(C)C)n(n3)c4ccc(cc4)[N+](=O)[O-] -154.361 25 5-[5-carbamoyl-1-(2,4-dichlorophenyl)-4H-pyrazol-3-yl]-2-(2,4- dichlorophenyl)pyrazole-3-carboxamide NC(=O)C1=[N](N=C(C1)c2cc(C(=O)N)n(n2)c3ccc(Cl)cc3Cl) c4ccc(Cl)cc4Cl -130.783 26 2-[5-[5-(1,3-benzothiazol-2-yl)-1,4-bis(4-chlorophenyl)pyrazol-3-yl]-2,4-bis(4- chlorophenyl)-4H-pyrazol-3-yl]-1,3-benzothiazole Clc1ccc(cc1)C2C(=N[N](=C2c3nc4ccccc4s3)c5ccc(Cl)cc5)c6nn(c7ccc(Cl)cc7)c (c8nc9cccc c9s8) c6c%10ccc(Cl)cc%10 -138.603 27 [2-(4-chlorophenyl)-5-[1-(4-chlorophenyl)-5-(2-hydroxybenzoyl)-4-phenyl-4H- pyrazol-3-yl]-4-phenyl-pyrazol-3-yl]-(2-hydroxyphenyl)methanone Oc1ccccc1C(=O)C2=[N](N=C(C2c3ccccc3)c4nn(c5ccc(Cl)cc5)c(C(=O)c6ccccc6O)c4c7ccccc7)c8ccc(Cl)cc8 -140.477 28 1-(4-chlorophenyl)-5-phenyl-3-(1H-pyrazol-3-yl)pyrazole-4-carbohydrazide NNC(=O)c1c(nn(c2ccc(Cl)cc2)c1c3ccccc3)c4cc[nH]n4 -137.395 29 4-[(4Z)-5-amino-4-[(4-bromophenyl)methylene]pyrazol-3-yl]-1,5-dimethyl-2- phenyl-pyrazol-3-one CN1N(C(=O)C(=C1C)C2=NN=C(N)/C/2=C\c3ccc(Br)cc3)c4ccccc4 -167.179 30 (E)-3-(2-hydroxyphenyl)-1-[1-phenyl-3-(2-thienyl)pyrazol-4-yl]prop-2-en-1-one Oc1ccccc1\C=C\C(=O)c2cn(nc2c3cccs3)c4ccccc4 -98.6882 31 5-methyl-4-[5-(4-oxochromen-3-yl)-4,5-dihydro-1H-pyrazol-3-yl]-1,2- dihydropyrazol-3-one CC1=C(C(=O)NN1)C2=NNC(C2)C3=COc4ccccc4C3=O -138.46 32 5-amino-N-(1,3-benzothiazol-2-yl)-3-(1,3-diphenylpyrazol-4-yl)-1H-pyrazole-4- carboxamide Nc1[nH]nc(c2cn(nc2c3ccccc3)c4ccccc4)c1C(=O)Nc5nc6ccccc6s5 -145.914 33 3-(5-hydroxy-3-methyl-1-phenyl-pyrazol-4-yl)-1H-pyrazole-5-carbohydrazide Cc1nn(c(O)c1c2cc([nH]n2)C(=O)NN)c3ccccc3 -117.006 34 diethyl 2-(4-bromophenyl)-5-(4-cyano-5-methyl-2-phenyl-pyrazol-3- yl)pyrazole-3,4-dicarboxylate CCOC(=O)c1c(nn(c2ccc(Br)cc2)c1C(=O)OCC)c3c(C#N)c(C)nn3c4ccccc4 -121.309
Set-3: Drugs from DrugBank Database
Owing to the output from bipyrazole dataset, which showed better inhibitory than tamoxifen, the next step utilized was to search DrugBank database because it was observed that certain drugs which are specific against a particular disease were found to be effective against other disease conditions as well, for example, Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes Figure 5 where it is evidenced that all drugs occupied clearly within the geometric space of the protein. From the table, out of 15 drugs, only 11 are finalized to consider for further analysis. This is because the four drugs viz., Bazedoxifene, Lapatinib, Raloxifene and Dabrafenib found to be anti-cancer drugs and hence omitted from the list.
Consensus Scoring to enrich drugs active against ERα:
It has been reported recently that consensus scoring, which combines multiple scoring functions, leads to higher hit-rates in virtual library screening studies [50] and presented an idealized computer experiment to explore how consensus scoring works based on the assumption that the error of a scoring function is a random number in a normal distribution. Many studies suggested that implementing consensus-scoring approaches enhances the performance by compensating for the deficiencies of the scoring functions with each other Screening analysis of DrugBank database drugs against ERα resulted in 11 drugs and all these drugs are subjected to consensus scoring using 5 scoring schemes such as MolDock score of Molegro, mcule, SwissDock, Pose & Rank and DSX respectively. Here, we chose the "rank-by-number" strategy to pool the output of multiple scoring functions. This is because, this strategy was reported to outperform the other techniques such as "rank-by-rank" and "rankby-vote" as the rank-by-number strategy summarized most of the information [56] Each scoring function was applied to generate three classes based on the obtained dock scores followed by ranking the best conformations. Classes were generated for all scoring functions and instead of taking an average, rank-bynumber technique [57] was employed to finalize best compounds. The ranks obtained from each of the scoring functions were added to give the rank-sum. The benefit of rank-by-number technique is that the each individual score involvement for a rank can certainly be split out for illustrative purposes [58] . The rank sums obtained for 11 drugs against five scoring functions were in the range 5 to 15, with 5 being low rank and 15 being first and best rank, respectively (Table 6 ). Therefore, finally from 11 drugs, the top five compounds with rank-sums 15 -12 (Lomitapide, Itraconazole, Cobicistat, Azilsartanmedoxomil, and Zafirlukast) are finalized. Further work shall be carried out to study their affinity of binding and inhibitory characteristics against ERα in a breast cancer cell line MCF-7. [2-phenyl-7-(3,4,5-trimethoxy-phenyl) -pyrazolo [1,5-a] pyrimidine-5-carbonyl]-piperazin-1-yl}-methanone and favourable interactions were observed with Thr347. In our search to unearth entirely novel compounds, bipyrazole nucleus compounds were analyzed which resulted in with -175.9 kcal/mol binding affinity with the receptor and favourable H-bond interaction with Thr347. After realizing this novel inhibitor, 2035 FDA approved drugs from DrugBank database were screened to study their efficacy against ERα, resulted in 15 such drugs with binding affinities greater than tamoxifen ranging from -164.66 to -187.12 kcal per mol. After eliminating 4 anti-cancer drugs, the remaining 11 drugs are subjected to consensus scoring using MolDock score of Molegro, mcule, SwissDock, Pose&Rank and DSX. Consensus analysis resulted in top ranks for 5 drugs viz., Lomitapide, Itraconazole, Cobicistat, Azilsartanmedoxomil, and Zafirlukast, which were 331 ©Biomedical Informatics (2019) selected further to assess their experimental activity in an MCF-7 cell line.
